Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07376265 · ClinicalTrials.gov registry record
A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,249
- Enrollment target
NCT07376265 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,249 participants.
The verdict
NCT07376265 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,249 participants
- Enrollment target
Study Summary
This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in northern Portugal. The study aimed to assess the comparative effectiveness of sacubitril/valsartan (SAC/VAL) versus angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients with heart failure with reduced ejection fraction (HFrEF).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,249 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2024-04-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07376265
The ClinicalTrials.gov registry entry for NCT07376265 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07376265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07376265 about?
NCT07376265 is a clinical study titled "A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients". This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in northern Portugal. The study aimed to assess the comparative effectivene...
What is the current status of trial NCT07376265?
This trial is currently completed. The enrollment target is 1,249 participants. The study started on 2023-10-20. Estimated completion is 2024-04-11.
Who is sponsoring clinical trial NCT07376265?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.